1. Home
  2. MMU vs EVO Comparison

MMU vs EVO Comparison

Compare MMU & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Managed Municipals Fund Inc.

MMU

Western Asset Managed Municipals Fund Inc.

HOLD

Current Price

$9.37

Market Cap

500.4M

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.52

Market Cap

568.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMU
EVO
Founded
1992
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
500.4M
568.6M
IPO Year
1994
2007

Fundamental Metrics

Financial Performance
Metric
MMU
EVO
Price
$9.37
$1.52
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $4.24
AVG Volume (30 Days)
★ 436.2K
80.7K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 4.92%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$20.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.71
$1.33
52 Week High
$10.71
$4.27

Technical Indicators

Market Signals
Indicator
MMU
EVO
Relative Strength Index (RSI) 50.73 46.19
Support Level $9.30 $1.50
Resistance Level $10.33 $1.97
Average True Range (ATR) 0.19 0.05
MACD 0.07 0.02
Stochastic Oscillator 60.44 47.50

Price Performance

Historical Comparison
MMU
EVO

About MMU Western Asset Managed Municipals Fund Inc.

Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax, consistent with the preservation of principal. The fund predominantly invests in long-term investment-grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: